Compare Novartis AG (NVS) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Palantir Technologies Inc — how do they compare? Novartis AG trades at $138.17 (market cap $262.64B), while Palantir Technologies Inc trades at $169.48 (market cap $409.24B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Novartis AG pays a 3.44% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| NVS | PLTR | |
|---|---|---|
Market Cap | $262.64B | $409.24B |
Sector | Health | Technology |
52-Week High | $168.62 | $207.18 |
52-Week Low | $121.80 | $107.27 |
Enterprise Value | $303.97B | $400.04B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Palantir (PLTR) trades at $170.30, down 2.31% on the day, with technical indicators showing neutral signals amid strong fundamental performance. The company reported exceptional Q2 2026 results with EPS of $0.41 beating expectations by 19%, while revenue growth accelerated to 93% year-over-year. Recent news highlights the strategic Nebius partnership for sovereign AI infrastructure, positioning Palantir to address growing enterprise demand for private AI deployment solutions.
While valuation metrics remain elevated with P/E of 145.6 and P/S of 71.1, the company's 49% net margin and 38.4% ROE demonstrate strong profitability. The consensus price target of $211.38 suggests 24% upside potential, though competitive pressures and high expectations create execution risks. Investors face the tension between premium valuation and exceptional growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
